How xenon works: neuro and cardioprotection mechanisms

Detalhes bibliográficos
Autor(a) principal: Morais, R
Data de Publicação: 2014
Outros Autores: Andrade, L, Lourenço, A, Tavares, J
Tipo de documento: Artigo
Idioma: por
Título da fonte: Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
Texto Completo: http://hdl.handle.net/10400.4/1725
Resumo: INTRODUCTION: The Xenon, a noble gas, has anesthetics properties, associated with remarkable hemodynamic stability as well as cardioprotective, neuroprotective proprieties. Its physicochemical characteristics give him a quick induction and emergence of anesthesia, being free of deleterious effects in all organs and showing no teratogenicity. Such properties have led to a growing interest in improving the knowledge about this noble gas, in order to assess the mechanisms of neuro and cardioprotection induced and to assess the clinical indications for its use. MATERIAL AND METHODS: Qualitative review of clinical trials on anesthesia with xenon. Studies were identified from MEDLINE and by hand-searching, using the following keywords: xenon, xenon anestesia, xenon neuroprotection, xenon cradioprotection. RESULTS: After several studies, including two randomized multicenter controlled trials, the use of xenon as an anesthetic in patients ASA I-II was approved in March 2007. However his use in clinical practice has been strongly limited by it's high price. It seems unlikely that the advantages it offers in relation to other anesthetics justify it's use in patients ASA I-II. Although, xenon may be a valuable asset in the reduction of co-morbilities and mortality in anesthesia of patients ASA III-IV, unfortunately, there are no large randomized control studies to prove it. DISCUSSION: Unfortunately, there are still no randomized or multicentric studies showing a favourable cost-benefit profile of xenon in ASA III-IV patients vs. other anaesthetics. CONCLUSION: The usefulness of xenon in Anesthesiology requires more studies to be defined.
id RCAP_f4cd5ad3b3c0b039dd64b25827162085
oai_identifier_str oai:rihuc.huc.min-saude.pt:10400.4/1725
network_acronym_str RCAP
network_name_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository_id_str 7160
spelling How xenon works: neuro and cardioprotection mechanismsComo Funciona o Xénon: Mecanismos de Neuro e CardioprotecçãoPrecondicionamento Isquémico MiocárdicoAnestésicos InalatóriosFármacos NeuroprotectoresXénonINTRODUCTION: The Xenon, a noble gas, has anesthetics properties, associated with remarkable hemodynamic stability as well as cardioprotective, neuroprotective proprieties. Its physicochemical characteristics give him a quick induction and emergence of anesthesia, being free of deleterious effects in all organs and showing no teratogenicity. Such properties have led to a growing interest in improving the knowledge about this noble gas, in order to assess the mechanisms of neuro and cardioprotection induced and to assess the clinical indications for its use. MATERIAL AND METHODS: Qualitative review of clinical trials on anesthesia with xenon. Studies were identified from MEDLINE and by hand-searching, using the following keywords: xenon, xenon anestesia, xenon neuroprotection, xenon cradioprotection. RESULTS: After several studies, including two randomized multicenter controlled trials, the use of xenon as an anesthetic in patients ASA I-II was approved in March 2007. However his use in clinical practice has been strongly limited by it's high price. It seems unlikely that the advantages it offers in relation to other anesthetics justify it's use in patients ASA I-II. Although, xenon may be a valuable asset in the reduction of co-morbilities and mortality in anesthesia of patients ASA III-IV, unfortunately, there are no large randomized control studies to prove it. DISCUSSION: Unfortunately, there are still no randomized or multicentric studies showing a favourable cost-benefit profile of xenon in ASA III-IV patients vs. other anaesthetics. CONCLUSION: The usefulness of xenon in Anesthesiology requires more studies to be defined.RIHUCMorais, RAndrade, LLourenço, ATavares, J2014-08-13T11:27:58Z20142014-01-01T00:00:00Zinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleapplication/pdfhttp://hdl.handle.net/10400.4/1725porActa Med Port. 2014;27(2):259-65.info:eu-repo/semantics/openAccessreponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAP2023-07-11T14:23:00Zoai:rihuc.huc.min-saude.pt:10400.4/1725Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireopendoar:71602024-03-19T18:04:11.823627Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse
dc.title.none.fl_str_mv How xenon works: neuro and cardioprotection mechanisms
Como Funciona o Xénon: Mecanismos de Neuro e Cardioprotecção
title How xenon works: neuro and cardioprotection mechanisms
spellingShingle How xenon works: neuro and cardioprotection mechanisms
Morais, R
Precondicionamento Isquémico Miocárdico
Anestésicos Inalatórios
Fármacos Neuroprotectores
Xénon
title_short How xenon works: neuro and cardioprotection mechanisms
title_full How xenon works: neuro and cardioprotection mechanisms
title_fullStr How xenon works: neuro and cardioprotection mechanisms
title_full_unstemmed How xenon works: neuro and cardioprotection mechanisms
title_sort How xenon works: neuro and cardioprotection mechanisms
author Morais, R
author_facet Morais, R
Andrade, L
Lourenço, A
Tavares, J
author_role author
author2 Andrade, L
Lourenço, A
Tavares, J
author2_role author
author
author
dc.contributor.none.fl_str_mv RIHUC
dc.contributor.author.fl_str_mv Morais, R
Andrade, L
Lourenço, A
Tavares, J
dc.subject.por.fl_str_mv Precondicionamento Isquémico Miocárdico
Anestésicos Inalatórios
Fármacos Neuroprotectores
Xénon
topic Precondicionamento Isquémico Miocárdico
Anestésicos Inalatórios
Fármacos Neuroprotectores
Xénon
description INTRODUCTION: The Xenon, a noble gas, has anesthetics properties, associated with remarkable hemodynamic stability as well as cardioprotective, neuroprotective proprieties. Its physicochemical characteristics give him a quick induction and emergence of anesthesia, being free of deleterious effects in all organs and showing no teratogenicity. Such properties have led to a growing interest in improving the knowledge about this noble gas, in order to assess the mechanisms of neuro and cardioprotection induced and to assess the clinical indications for its use. MATERIAL AND METHODS: Qualitative review of clinical trials on anesthesia with xenon. Studies were identified from MEDLINE and by hand-searching, using the following keywords: xenon, xenon anestesia, xenon neuroprotection, xenon cradioprotection. RESULTS: After several studies, including two randomized multicenter controlled trials, the use of xenon as an anesthetic in patients ASA I-II was approved in March 2007. However his use in clinical practice has been strongly limited by it's high price. It seems unlikely that the advantages it offers in relation to other anesthetics justify it's use in patients ASA I-II. Although, xenon may be a valuable asset in the reduction of co-morbilities and mortality in anesthesia of patients ASA III-IV, unfortunately, there are no large randomized control studies to prove it. DISCUSSION: Unfortunately, there are still no randomized or multicentric studies showing a favourable cost-benefit profile of xenon in ASA III-IV patients vs. other anaesthetics. CONCLUSION: The usefulness of xenon in Anesthesiology requires more studies to be defined.
publishDate 2014
dc.date.none.fl_str_mv 2014-08-13T11:27:58Z
2014
2014-01-01T00:00:00Z
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://hdl.handle.net/10400.4/1725
url http://hdl.handle.net/10400.4/1725
dc.language.iso.fl_str_mv por
language por
dc.relation.none.fl_str_mv Acta Med Port. 2014;27(2):259-65.
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.source.none.fl_str_mv reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron:RCAAP
instname_str Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron_str RCAAP
institution RCAAP
reponame_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
collection Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository.name.fl_str_mv Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
repository.mail.fl_str_mv
_version_ 1799131705110429696